Pharmaceutical supply chains are increasingly adopting AI to address significant challenges, including inaccuracies in demand forecasting and systemic inefficiencies.
According to Natalia Andreyeva, vice president of market strategy at 4flow, traditional forecasting tools in the pharmaceutical sector often have a 30% to 40% error rate due to their inability to adapt to rapid changes in the environment, such as regulatory shifts and market demands. Many companies still rely on fragmented planning systems that fail to integrate effectively, leading to inefficiencies and waste, with 1% to 3% of products going to waste due to shelf-life expirations. These issues highlight the urgent need for more cohesive and responsive planning strategies.
AI is proving particularly beneficial in logistics and disruption management, where it can provide immediate insights into supply chain impacts. With a significant portion of pharmaceutical products requiring temperature control, any delays can jeopardize product quality and availability. AI tools can help measure the effects of disruptions and offer tailored solutions, enhancing both operational efficiency and patient safety.
Looking ahead, the industry is shifting towards viewing AI not just as a point solution but as a catalyst for organizational transformation. While automation is set to alleviate repetitive tasks, Andreyeva emphasizes that human oversight, especially in regulatory compliance, will remain essential. This dual approach of leveraging AI while maintaining human expertise may be crucial for the future resilience of pharmaceutical supply chains.